Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.

Innovation Building with BioEscalator, EnaraBio and Boehringer Ingelheim logos

Enara Bio, an SV Health backed start-up, was founded in 2016 using technology developed at the Francis Crick Institute, London. The company joined the BioEscalator, Oxford University’s biotech incubator, in 2018 as Ervaxx with five employees and has since developed two proprietary platforms EDAPT™ and Dark Antigen™, rebranded as Enara Bio and grown the team to twenty-seven. Enara Bio has utilised its strong relationship with Oxford academics, including immunopeptidomics expert Dr Nicola Ternette and Vaccitech’s Professor Adrian Hill, both of the Nuffield Department of Medicine, to develop its innovative technologies.  It will now utilise Boehringer’s wealth of big pharma development resources to help drive discoveries further towards the clinic.

The partnership will provide additional funding to advance Dark Antigen research along with further independent validation of Enara’s novel EDAPT™ platform.

We’re excited to be partnered with an innovation-led company that has built considerable expertise in cancer vaccines and immune-oncology - Kevin Pojasek, CEO Enara Bio

Read the full story on the BioEscalator website

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.